Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory Evaluation

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

3 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-08-02

Study Completion Date

2017-12-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to exploratorily evaluate the effect of vonoprazan 20 mg on sleep disturbance of patients with reflux esophagitis, who have heartburn and/or regurgitation and ≥ 6.0 in the Pittsburgh Sleep Quality Index (PSQI) global score despite the maintenance treatment with PPI other than vonoprazan.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease

NCT04799158

Non-Erosive Gastro-Esophageal Reflux Disease Heartburn

COMPLETED PHASE2

Special Drug Use Surveillance of Vonoprazan for "Maintenance Therapy of Reflux Esophagitis: Long-term Use"

NCT03214081

Reflux Esophagitis

COMPLETED

Therapeutic Effect of Vonoprazan Versus Dexlansoprazole in Treatment of Gastroesophageal Reflux Disease

NCT06778395

Vonoprazan Proton Pump Inhibitor Gastroesophageal Reflux Disease

COMPLETED PHASE4

Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis

NCT02388724

Erosive Esophagitis

COMPLETED PHASE3

Efficacy and Safety of Vonoprazan Compared to Lansoprazole in the Maintenance Treatment of Erosive Esophagitis

NCT02388737

Erosive Esophagitis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to evaluate the effect of vonoprazan on sleep disturbance in the participants under maintenance treatment for reflux esophagitis with proton pump inhibitor (PPI) other than vonoprazan after initial treatment.

Participants who have been diagnosed as reflux esophagitis based on Los Angeles (LA) Classification Grades A to D, undergoing maintenance treatment with PPI other than vonoprazan after initial treatment, and with Pittsburgh Sleep Quality Index (PSQI) global score \>= 6.0 at enrolment (VISIT 1) will be eligible for study entry and will be administered vonoprazan 20 mg once daily for 8 weeks.

Planned number of participants is 25. The study period is 9 weeks. The number of visits is 6visits.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Reflux Esophagitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vonoprazan 20 mg

Vonoprazan 20 mg orally administered once daily

Group Type EXPERIMENTAL

Vonoprazan

Intervention Type DRUG

Vonoprazan 20 mg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vonoprazan

Vonoprazan 20 mg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Participants who completed the initial treatment with PPIs (esomeprazole, omeprazole, rabeprazole, or lansoprazole) and have received high dose PPIs (esomeprazole 20 mg, omeprazole 20 mg, rabeprazole 10 mg, or lansoprazole 30 mg) for more than 8 weeks at the time of informed consent as maintenance treatment for LA Classification Grades A to D reflux esophagitis.
2. Participants who have heartburn and/or regurgitation.
3. Participants with reflux esophagitis related sleep disturbance, fulfilling at least one of following in a week before the baseline/start of administration.

* Difficulty in falling asleep for \> = 3 nights
* Nocturnal awaking or early morning awaking for \> = 3 nights
4. Participants whose heartburn and/or regurgitation at the time of informed consent were alleviated from initial treatment.
5. Participants with PSQI global score \> = 6.0
6. Participants who, in the opinion of the investigator, are capable of understanding the content of the study and complying with the protocol requirements.
7. Participants who can sign and date an informed consent form and information sheet prior to the initiation of the study procedures.
8. Male or female participants aged 20 years or older at the time of informed consent.
9. Therapeutic category: Ambulatory

Exclusion Criteria

1. Participants with Zollinger-Ellison syndrome.
2. Participants with diseases that affect sleep (chronic obstructive pulmonary disease, bronchitis asthma, sleep apnea syndrome, mental disorder, etc.)
3. Nightshift workers.
4. Participants who have a plan to travel beyond three time zones during the study.
5. Participants with a history of, concurrent, or suspicious functional dyspepsia or functional heartburn based on Rome IV criteria.
6. Participants with history of surgery or treatment affecting gastroesophageal reflux (fundoplication or dilation for esophageal stenosis \[except for Schatzki's ring\], etc.).
7. Participants with an esophagus-related complication (eosinophilic esophagitis, esophageal varices, scleroderma, viral or fungal infection, esophageal stenosis, etc.), a history of radiotherapy or cryotherapy of the esophagus, a caustic or physiochemical trauma (esophageal sclerotherapy, etc.). However, participants with Schatzki's ring (mucosal tissue ring around inferior esophageal sphincter) or Barrett's esophagus are allowed to be included.
8. Participants with a history of gastrectomy, gastrointestinal resection, or vagotomy.
9. Participants who took antidepressant agents or anti-anxiety agents within 8 weeks before the time of informed consent.
10. Participants who took H2 receptor antagonist within 8 weeks before the time of informed consent.
11. Participants planning to take prohibited concomitant medications during the study period.
12. Participants who have any of the following abnormal clinical laboratory test values at the screening (VISIT 1):

* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> upper limit of normal (ULN)
* Bilirubin (Total bilirubin) \> ULN
13. Participants with a malignant tumor.
14. Participants who are pregnant, breast-feeding, possibly pregnant, or planning to become pregnant.
15. Participants who have serious renal diseases.
16. Participants with the conditions listed under administration contraindication in the vonoprazan package insert.
17. Participants participating in other clinical studies.
18. Participants who have been determined as inappropriate participants by the investigator.

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No